Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC
Status:
Completed
Trial end date:
2019-12-12
Target enrollment:
Participant gender:
Summary
This clinical trial studies the effect of radium-223 when added to sipuleucel-T for treating
castrate-resistant prostate cancer that has spread to the bone. Sipuleucel-T is an autologous
cellular immunotherapy designed to stimulate an immune response against prostate cancer. It
has been suggested that the immune response may be strengthened by radiation therapy.
Therefore this study is testing whether radium-223 added to sipuleucel-T increases the immune
response and anti-tumor effect against prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins